Anesth Analg 1999;89:1096
© 1999 International Anesthesia Research Society
CARDIOVASCULAR ANESTHESIA
Aprotinin Pretreatment Diminishes Postischemic Myocardial Contractile Dysfunction in Dogs
Robert J. McCarthy, PharmD,
Kenneth J. Tuman, MD,
Christopher OConnor, MD, and
Anthony D. Ivankovich, MD
Department of Anesthesiology, Rush Medical College at Rush-Presbyterian-St. Lukes Medical Center, Chicago, Illinois
Address correspondence and reprint requests to Kenneth J. Tuman, MD, Rush Medical College at Rush-Presbyterian-St. Lukes Medical Center, 1653 W. Congress Parkway, Chicago, IL 60612.
We evaluated the effect of aprotinin, administered before the onset of acute regional myocardial ischemia, on reversible contractile dysfunction induced by ischemia and reperfusion in pentobarbital-anesthetized dogs. Animals were randomized to receive either aprotinin 30,000 kallikrein inactivator units (KIU)/kg and 7000 KIU · kg-1 · hr-1 (n = 8) or equivalent volumes of 0.9% sodium chloride (n = 7) IV 60 min before a 15-min interruption of circumflex coronary artery blood flow and then reperfusion. There were no intra- or intergroup differences in hemodynamic variables or regional myocardial mechanics (sonomicrometry) before onset of ischemia. Immediately before reperfusion, systolic dysfunction characterized by significantly decreased percent systolic shortening was present in the circumflex coronary artery area of both study groups. After reestablishment of perfusion, aprotinin animals had preserved percent systolic shortening whereas saline animals exhibited regional systolic dysfunction. Regional myocardial contractility as assessed by the slope Mw of the preload recruitable stroke work relation was preserved during reperfusion in animals who received aprotinin but depressed in the control group. We conclude that functional recovery from myocardial ischemia-reperfusion injury at normothermia is improved by IV administration of aprotinin before the onset of acute regional myocardial ischemia in physiologically intact dogs.
Implications: Administration of clinically relevant doses of aprotinin IV before the onset of regional myocardial ischemia, in contrast to control conditions, preserved regional systolic function and contractility at baseline values after reestablishment of myocardial perfusion in dogs.
This article has been cited by other articles:

|
 |

|
 |
 
M. D. McEvoy, M. J. Sabbagh, A. G. Taylor, J. A. Zavadzkas, C. N. Koval, R. E. Stroud, R. L. Ford, J. E. McLean, S. T. Reeves, R. Mukherjee, et al.
Aprotinin Modifies Left Ventricular Contractility and Cytokine Release After Ischemia-Reperfusion in a Dose-Dependent Manner in a Murine Model
Anesth. Analg.,
February 1, 2009;
108(2):
399 - 406.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. D. McEvoy, S. T. Reeves, J. G. Reves, and F. G. Spinale
Aprotinin in Cardiac Surgery: A Review of Conventional and Novel Mechanisms of Action
Anesth. Analg.,
October 1, 2007;
105(4):
949 - 962.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. G. Kevin, E. Novalija, and D. F. Stowe
Reactive Oxygen Species as Mediators of Cardiac Injury and Protection: The Relevance to Anesthesia Practice
Anesth. Analg.,
November 1, 2005;
101(5):
1275 - 1287.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. A. Khan, C. Bianchi, P. Voisine, J. Feng, J. Baker, M. Hart, M. Takahashi, G. Stahl, and F. W. Sellke
Reduction of myocardial reperfusion injury by aprotinin after regional ischemia and cardioplegic arrest
J. Thorac. Cardiovasc. Surg.,
October 1, 2004;
128(4):
602 - 608.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. H Olivencia-Yurvati, N. Wallace, S. Ford, and R. T Mallet
Leukocyte filtration and aprotinin: synergistic anti-inflammatory protection
Perfusion,
January 1, 2004;
19(1_suppl):
S13 - S19.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A. Bull and J. Maurer
Aprotinin and preservation of myocardial function after ischemia-reperfusion injury
Ann. Thorac. Surg.,
February 1, 2003;
75(2):
S735 - 739.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Paparella, T.M. Yau, and E. Young
Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update
Eur. J. Cardiothorac. Surg.,
February 1, 2002;
21(2):
232 - 244.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Hendrikx, F. Rega, L. Jamaer, T. Valkenborgh, H. Gutermann, and U. Mees
Na+/H+-exchange inhibition and aprotinin administration: promising tools for myocardial protection during minimally invasive CABG
Eur. J. Cardiothorac. Surg.,
May 1, 2001;
19(5):
633 - 639.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. A. Gramlich and S. D. Barnes
Aprotinin Use in Pediatric Cardiac Surgery
Seminars in Cardiothoracic and Vascular Anesthesia,
March 1, 2001;
5(1):
117 - 121.
[Abstract]
[PDF]
|
 |
|
|